Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

Kyoto University Hospital, Kyoto, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:5City/State/Province:Kyoto
Treatments:Biologic therapyHospital:Kyoto University Hospital
Drugs:Journal:Link
Date:Apr 2011

Description:

Patients:
This study involved 48 patients with previously treated advanced non-small cell lung cancer. The median age of the group was 62 years and 52% were male.

Treatment:
Patients were treated with the biologic therapy called erlotinib, which is a small molecular inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in cell growth and survival.

Toxicities:
There was one treatment-related death due to pneumonia. Also, grade 3-4 anorexia, fatigue, and stomatitis (inflammation of the mouth) was reported.

Results:
The reported median overall survival was 7.5 months.

Support:
Researchers received funding from pharmaceutical companies Taiho Pharmaceuticals and Chugai Pharmaceuticals.

Correspondence: Dr. Kazuhiro Yanagihara; email: [email protected]



Back